
1 Supplementary Figure S5



С

Antibody (Clone 9D9)	αCTLA-4 (mlgG2b)			αCTLA-4 ^{DLE} (mlgG2b.DLE)		
Dose (µg)	10	30	100	10	30	100
Cmax (µg/mL)	5.3	15.4	53.9	4.6	14.4	35.7
Tmax (h)	6	6	3	9	6	9
T1/2 (h)	60.0	52.9	54.1	49.9	44.8	48.4
AUC,0-last (h*µg/mL)	372.3	1157.4	4142.1	261.9	925.0	2751.9
Vz (mL)	2.3	2.0	1.9	2.7	2.1	2.5
CI (mL/h)	0.027	0.026	0.024	0.038	0.032	0.036
Lambda z (1/h)	0.012	0.013	0.013	0.014	0.015	0.014

2

Supplementary Figure S5. Pharmacokinetics of mouse α **CTLA-4**^{DLE}**.** Concentration – time 3 curves from plasma collected at indicated time points from Balb/c mice administered 10, 30 or 4 100 μg of (a) αCTLA-4 (clone 9D9, αCTLA-4) or (b) Fc-enhanced αCTLA-4 (clone 9D9, αCTLA-5 4^{DLE}) antibodies on study day 0. Plasma drug concentrations were quantified using a qualified 6 7 ligand capture ELISA assay. (c) Pharmacokinetic parameter from a non-compartmental analysis 8 (NCA) analysis performed on concentration - time data from (a) and (b). Abbreviations. Cmax, concentration maximum; Tmax, time maximum; T1/2, half-life; AUC, area under the curve; Vz, 9 volume of distribution; CI, clearance. 10